Welcome to WWW.CUREPEYRONIES.NET   A web site
dedicated solely to news about Peyronie's Disease
WWW.CUREPEYRONIES.NET
HOME PAGE
<div style="background-color: none transparent;"><a href="http://www.ikiloop.com/" title="buy">here</a></div>
<div style="background-color: none transparent;"><a href="http://www.ikiloop.com/" title="buy">here</a></div>
DOES THE USE OF THIS DRUG CAUSE
PEYRONIES DISEASE?  
MANY MEN SAY YES!
PRODUCT NEGLIGENCE LAWSUITS FILED
AGAINST MERCK. THE SCIENTIFIC EVIDENCE
SHOWS...
A Short History Of Finasteride And How It Works

In an isolated village in the Southwestern Dominican
Republic, 2% of the live births were known as
guevedoces (translated as-penis at 12 years). They were
also known as machibembras, "first woman, then man."
As children they appeared to be girls, but  subsequently
turned into men at puberty. The scientific term for their
condition is male pseudohermaphroditism. The underlying
pathology of their condition was due to a deficiency of the
enzyme, 5-
alpha Reductase. This deficiency suppressed
levels of the male hormone, dihdrotestosterone (DHT) and
caused alteration of the male child's sexual development.  

Photos of these guevedoces:
Appearance is that of a
female through
undescended testes are
present
Still has the
appearance of a
female
After puberty they
resemble other
Dominican men except:
No hairline recession
None had acne
Prostate remained small
In the 1970s, Dr. Julianne Imperato-McKinley conducted
an expedition to this area to investigate this condition.  
Four years later, she discussed her findings at a medical
conference on birth defects. The following year a
monograph of this conference was read by a high level
executive at Merck who focused on the description that
individuals with this condition, "The prostate, however,
remains small..."  This was an eureka moment for Merck's
chief research officer.  DHT causes prostate growth and
lowering levels of DHT results in shrinkage of the
prostate.  Merck then began research eventually leading
to the development of a drug that decreased levels of
DHT.  This resulted in a smaller prostate in order to treat
benign prostatic hyperplasia (BHP). This medical
condition is a non-cancerous enlarged prostate which  
blocks urine flow, interrupts sleep and can cause serious
infections.  

In 1992, finasteride (5mg) was approved by the Federal
Drug Administration for the treatment of benign prostatic
hyperplasia (BHP) and marketed by Merck under the
name of
Proscar.  Men treated with Proscar noticed hair
growth in the front and top of their head. Hair loss in
these areas of male head are typical of male pattern
baldness also known as androgenic alopecia. In 1997,
Merck received Federal Drug Administration approval for a
much lower dose (1mg) of finasteride to treat male pattern
baldness. This drug was marketed under the name of
Propecia.     
HTML Comment Box is loading comments...
Xiaflex - Is It
The Magic
Bullet?
A Novel &
Improved
Injection
Technique
?
A New Feature
Has Been
Added To This
Site. See The
Drop Down
Menu At The
Top Of This
Page..   
What Do You
Think? Have A
Suggestion,
Comment Or
Question?
Click Here